
STUDY

Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients (TOURMALINE-MM2)

Population: N = 705

Primary endpoint: Progression-free survival **Eligibility:** Adult patients with MM ineligible for ASCT due to age (≥65 years) or comorbidities; No prior treatment for MM; ECOG 0–2



EFFICACY Median progression-free survival Treatment arm 35.3 months Control arm 21.8 months P=0.073Median progression-free survival, high risk cytogenetic group Treatment arm 23.8 months Control arm 18.0 months P=0.0019**Response rates** Treatment arm vs Control arm % 20 **14** % **VGPR** CR PR NR P<0.001

